Answers are grounded in this paper and cite their sources.
Hepatitis B surface antigen (HBsAg) seroclearance is considered to be one of the best surrogate endpoints of functional cure for hepatitis B virus (HBV) infection. However, evidence regarding the relationship between achieving HBsAg seroclearance or a low baseline HBsAg level, and long-term clinical outcomes in Japanese patients with chronic HBV infection remains to be confirmed in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Okada et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: